Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Effect of age, gender, and obesity on midazolam kinetics.
D J Greenblatt; D R Abernethy; A Locniskar; J S Harmatz; R A Limjuco; R I Shader (Profiled Author: Darrell Abernethy)
Anesthesiology 1984;61(1):27-35.
AbstractThe effects of age, sex, and obesity on the kinetics of single intravenous (iv) and oral doses of midazolam were evaluated in healthy volunteers who received 2.5-5 mg of iv midazolam on one occasion and 5-10 mg orally on another. Kinetics were determined from multiple plasma midazolam concentrations measured during 24 h after dosage. Midazolam elimination half-life (t1/2) after iv dosage was significantly prolonged in elderly (aged 60-74 yr) versus young (24-33 yr) males (5.6 vs. 2.1 hours, P less than 0.01) and total clearance was significantly reduced (4.4 vs. 7.8 ml X min-1 X kg-1, P less than 0.01), leading to increased systemic availability of the oral dose (50% vs. 41%, P less than 0.05). However total volume of distribution calculated by the area method (Vd) (1.6 vs. 1.3 1/kg) and protein binding (3.5 vs. 3.4% unbound) did not differ between groups. Among women there were no significant differences between elderly (64-79 yr) and young (23-37 yr) volunteers in t1/2 (4.0 vs. 2.6 h), clearance (7.5 vs. 9.4 ml X min-1 X kg-1), Vd (2.1 vs. 2.0 1/kg), protein binding (3.7% vs. 3.7% unbound), or oral bioavailability (38% vs. 36%). In obese volunteers (mean weight 117 kg; 173% of ideal weight) versus control subjects of normal weight (66 kg, 95% of ideal weight) matched for age, sex, and smoking habits, midazolam Vd was increased significantly (311 vs. 114 1, P less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
Scientific Context
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Related Publications
-
1.
1984D R Abernethy; D J Greenblatt; M Divoll; R B Smith; R I Shader
The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam.
Clinical pharmacokinetics 1984;9(2):177-83. -
2.
2005Larissa A Wenning; M Gail Murphy; Laura P James; Jeffrey L Blumer; James D Marshall; John Baier; Ann O Scheimann; Deborah L Panebianco; Ling Zhong; Roy Eisenhandler; et al.
Pharmacokinetics of famotidine in infants.
Clinical pharmacokinetics 2005;44(4):395-406. -
3.
1983D J Greenblatt; M Divoll; D R Abernethy; L J Moschitto; R B Smith; R I Shader
Alprazolam kinetics in the elderly. Relation to antipyrine disposition.
Archives of general psychiatry 1983;40(3):287-90.

Appears in this Publication








